Arrowhead Pharmaceuticals Valuation
Is ARWR * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ARWR * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ARWR *'s fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ARWR *'s fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ARWR *?
Key metric: As ARWR * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is ARWR *'s PS Ratio? | |
|---|---|
| PS Ratio | 11.1x |
| Sales | US$256.21m |
| Market Cap | US$2.84b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 10.7x |
| Enterprise Value/EBITDA | -16.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ARWR *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 13.1x | ||
LAB B Genomma Lab Internacional. de | 1.4x | 9.9% | Mex$24.0b |
CPRX Catalyst Pharmaceuticals | 5.7x | 12.7% | US$2.5b |
ZLAB Zai Lab | 7.6x | 34.0% | US$2.8b |
688266 Suzhou Zelgen BiopharmaceuticalsLtd | 37.8x | 59.6% | CN¥17.7b |
ARWR * Arrowhead Pharmaceuticals | 11.1x | 25.5% | Mex$2.8b |
Price-To-Sales vs Peers: ARWR * is good value based on its Price-To-Sales Ratio (11.1x) compared to the peer average (22.1x).
Price to Sales Ratio vs Industry
How does ARWR *'s PS Ratio compare vs other companies in the Global Biotechs Industry?
| 275 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 275 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: ARWR * is expensive based on its Price-To-Sales Ratio (11.1x) compared to the Global Biotechs industry average (9.6x).
Price to Sales Ratio vs Fair Ratio
What is ARWR *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 11.1x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ARWR *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a
Incyte
US$13.8b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally.
INCY *
US$1,486.00
7D
0%
1Y
n/a